[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
[junkie-alert style=”white”] The American Brachytherapy Society’s journal, Brachytherapy, has published a special issue focused on MRI-based prostate brachytherapy1. This issue contains 15 individual papers describing all elements of MRI-based prostate brachytherapy, from key clinical techniques to the efficacy and cost effectiveness of the procedure according to C4 Imaging LLC. [/junkie-alert]
A key paper2 describes the use of positive contrast magnetic resonance imaging markers (Sirius™ MRI Marker) when treating prostate cancer and concludes the procedure is feasible, accurate and reduces uncertainties. The study was conducted at the MD Anderson Cancer Center, Houston, Texas.
Brachytherapy, or radioactive seed implantation is a cost-effective option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 tiny radioactive seeds into the prostate. It’s minimally invasive, effective and convenient, with a low incidence of erectile dysfunction and other side effects. Radiation released from the seeds penetrates the prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy can be excellent, but depend greatly on the quality of the implant.
Steven J. Frank MD, Founder and Chairman of C4 Imaging on the published data said, “The recently published data on MRI-guided prostate brachytherapy, also known as MRI assisted radiosurgery or MARS, demonstrates that it leads to high quality treatment that minimizes the delivery of radiation to critical anatomical structures around the prostate.” He noted, “If seeds can be more precisely localized with MRI in the prostate, it may lead to more effective treatment and better patient outcomes for patients with prostate cancer.”
“This significant publication further demonstrates the evolving and increasingly important role of MRI in managing prostate cancer patients,” added Andrew Bright, President and CEO of C4 Imaging. “We believe that all men diagnosed with prostate cancer should, at a minimum, be able to discuss the benefits of MRI-guided brachytherapy with their physician.”
1. Brachytherapy: Volume 16, Number 4, July – August 2017
2. Brachytherapy 16 (4), 761 – 769, 2017